Second serosurveillance study in The Netherlands for the evaluation of the Dutch National Immunisation Programme: the PIENTER 2 study
ISRCTN | ISRCTN20164309 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN20164309 |
Secondary identifying numbers | N/A |
- Submission date
- 27/06/2007
- Registration date
- 27/06/2007
- Last edited
- 18/03/2013
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr F.R.M. van der Klis
Scientific
Scientific
National Institute of Public Health and Environmental Protection (RIVM)
afdeling LIS
P.O. Box 1
Bilthoven
3720 BA
Netherlands
Phone | +31 (0)30 274 2272 |
---|---|
fiona.van.der.klis@rivm.nl |
Study information
Study design | Observational, cross-section survey |
---|---|
Primary study design | Observational |
Secondary study design | Cross-section survey |
Study setting(s) | Not specified |
Study type | Screening |
Scientific title | |
Study acronym | PIENTER 2 |
Study objectives | The age-specific seroprevalence of a cross-section of the Dutch population for the vaccinations used in the Dutch National Immunisation Programme. |
Ethics approval(s) | Approval received from the local ethics committee (Stichting Therapeutische Evaluatie Geneesmiddelen [STEG]) on the 11th October 2005 (ref: R05-044). |
Health condition(s) or problem(s) studied | Vaccination and the National Immunisation Program, infectious diseases |
Intervention | A blood sample and a questionnaire regarding health perception, diseases (including sexually transmitted), vaccination data. |
Intervention type | Other |
Primary outcome measure | The age-specific seroprevalence (immunity) for diseases included in the National Immunisation Program of the Dutch general population. As each participant is sampled only once, there will be only one timepoint measurement per person. The timepoint for the complete study population varies from February 2006 to June 2007. Because the participants represent a cross section of the Dutch population aged 0 to 80, we will be able to estimate the seroprevalence in the Dutch population in 2006-2007. |
Secondary outcome measures | 1. The age-specific seroprevalence against other infectious diseases, in particular those that might be vaccine preventable in the near future and against those diseases with a frequent subclinical course 2. The age-specific seroprevalence amongst the allochtonous populations (additional sample) 3. The age-specific seroprevalence amongst non-vaccinated orthodox reformed individuals (additional sample) As each participant is sampled only once, there will be only one timepoint measurement per person. The timepoint for the complete study population varies from February 2006 to June 2007. Because the participants represent a cross section of the Dutch population aged 0 to 80, we will be able to estimate the seroprevalence in the Dutch population in 2006-2007. |
Overall study start date | 06/02/2006 |
Completion date | 19/06/2007 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Not Specified |
Target number of participants | 7700 |
Key inclusion criteria | 1. Subject is part of the study sample 2. Aged 0 - 79 years old 3. Has received a personal invitation for the study 4. Subject has given written informed consent before start of the study |
Key exclusion criteria | Subject is an employee of the National Institute of Public Health and Environmental Protection (RIVM). |
Date of first enrolment | 06/02/2006 |
Date of final enrolment | 19/06/2007 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
National Institute of Public Health and Environmental Protection (RIVM)
Bilthoven
3720 BA
Netherlands
3720 BA
Netherlands
Sponsor information
National Institute of Public Health and Environmental Protection (RIVM) (The Netherlands)
Government
Government
P.O. Box 1
Bilthoven
3720 BA
Netherlands
Phone | +31 (0)30 274 9111 |
---|---|
info@rivm.nl | |
Website | http://www.rivm.nl/en/ |
https://ror.org/01cesdt21 |
Funders
Funder type
Government
The Netherlands Ministry of Health, Welfare and Sport (The Netherlands)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 19/10/2012 | Yes | No | |
Results article | results | 01/04/2014 | Yes | No |